Visual dysfunction in Parkinson disease without dementia

Uç, Ergun Y.; Rizzo, Matthew; Anderson, Steven W.; Qian, Shixing; Rodnitzky, Robert L.; Dawson, Jeffrey D.

doi:10.1212/01.wnl.0000191565.11065.11

Cited by 274 publications

(248 citation statements)

References 48 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…In a study of patients with schizophrenia, Slaghuis (1998) found that patients diagnosed with schizophrenia were impaired for moving and stationary gratings, with most consistent deficits at higher spatial frequencies. Unlike the present HD sample, patients diagnosed with Parkinson's disease (Uc et al, 2005) and schizophrenia (O'Donnell et al, 2006) can show dot motion deficits as well as impaired stationary contrast sensitivity. Thus, in Parkinson's disease, aging, and schizophrenia, the pattern of visual deficits frequently differs from that of HD gene carriers.…”

Section: Discussioncontrasting

confidence: 64%

“…Visual perceptual impairments have been reported in other neurodegenerative disorders. For example, patients with Parkinson's disease show deficits on tests of contrast sensitivity (Rodnitzky, 1998;Uc et al, 2005), color vision (Rodnitzky, 1998), and motion perception (Uc et al, 2005). In Alzheimer's disease, deficits in contrast sensitivity (Gilmore et al, 2005;Rizzo et al, 2002) and motion perception (Rizzo et al, 2002) have been described.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Visual perception in prediagnostic and early stage Huntington's disease

O’Donnell

Blekher

Weaver

et al. 2008

J Inter Neuropsych Soc

View full text Add to dashboard Cite

Disturbances of visual perception frequently accompany neurodegenerative disorders but have been little studied in Huntington's disease (HD) gene carriers. We used psychophysical tests to assess visual perception among individuals in the prediagnostic and early stages of HD. The sample comprised four groups, which included 201 nongene carriers (NG), 32 prediagnostic gene carriers with minimal neurological abnormalities (PD1); 20 prediagnostic gene carriers with moderate neurological abnormalities (PD2), and 36 gene carriers with diagnosed HD. Contrast sensitivity for stationary and moving sinusoidal gratings, and tests of form and motion discrimination, were used to probe different visual pathways. Patients with HD showed impaired contrast sensitivity for moving gratings. For one of the three contrast sensitivity tests, the prediagnostic gene carriers with greater neurological abnormality (PD2) also had impaired performance as compared with NG. These findings suggest that early stage HD disrupts visual functions associated with the magnocellular pathway. However, these changes are only observed in individuals diagnosed with HD or who are in the more symptomatic stages of prediagnostic HD. (JINS, 2008, 14, 446-453.)

show abstract

Section: Discussioncontrasting

confidence: 64%

Section: Introductionmentioning

confidence: 99%

Visual perception in prediagnostic and early stage Huntington's disease

O’Donnell

Blekher

Weaver

et al. 2008

J Inter Neuropsych Soc

View full text Add to dashboard Cite

show abstract

“…The CRAF test might help identify patients who have visual perception problems and are at risk of falls and will allow us to tailor a rehabilitation program accordingly. The exact etiology of visual dysfunction in PD is not fully understood; it may be related to retinal dopamine deficiency or higher order visual cortical dysfunction [12,23].…”

Section: Discussionmentioning

confidence: 99%

“…The increased visual dependence may also limit a patient's ability to compensate fully for gait disorders, particularly in situations involving sensory conflict caused by excessive visual motion [11]. Further studies suggest that visual dysfunction may also contribute to PD disability through influences on cognition and locomotion [12]. A better understanding of these events and their interrelationships will provide the underpinning for efforts to improve rehabilitation.…”

Section: Introductionmentioning

confidence: 99%

Subjective visual vertical perception and sense of smell in Parkinson disease

Khattab¹,

Docherty²,

Bagust³

et al. 2012

JRRD

View full text Add to dashboard Cite

Abstract-Thisarticle describes an open cross-sectional observational study involving 47 participants with Parkinson disease (PD) and 47 (age-and sex-matched) nondisabled controls without PD. The aim was to determine the profiles of subjective visual vertical (SVV) perception and sense of smell perception in both groups. There was a statistically significant difference (p < 0.001) between patients and controls on their smell test performance. Controls were more likely to correctly identify odors, with a median score of 10 out of 12 compared with 6.5 out of 12 for patients with PD. The median SVV error for the PD group when the frame was untilted was 0.75 degrees compared with 0.50 degrees for controls. This difference was statistically significant (p = 0.02). When the frame was tilted, the median SVV error for the PD group was 2.31 degrees compared with 2.00 degrees for controls (not statistically significant), with both groups showing similar distribution pattern of errors. There was no statistical correlation between number of correctly identified odors and an individual's SVV error. However, a statistically significant negative correlation (r = 0.45, p = 0.01) was found between Mini-Mental State Examination score and mean time taken to complete each rod and frame test in patients with PD, suggesting that SVV errors might be more correlated with cognitive function than with loss of sense of smell.

show abstract

“…9,[43][44][45] Visual perception and cognition abnormalities are associated with dysfunction ranging from retinal to cortical levels. 17 Visual dysfunction is associated with gait and balance impairment, and visual cues can improve freezing of gait.…”

Section: Visionmentioning

confidence: 99%

Non-motor Symptoms in Parkinson’s Disease

Uç¹,

Tippin²,

Chou³

et al. 2011

US Neurology

View full text Add to dashboard Cite

In addition to typical motor dysfunction (parkinsonism), diverse non-motor symptoms (NMS) are frequently observed in patients with Parkinsons disease (PD). Some NMS may antedate the diagnosis of PD. Examples of NMS include cognitive impairment, autonomic dysfunction, visual dysfunction, sleep abnormalities, and psychiatric disorders. NMS are associated with wide-ranging abnormalities in extranigral dopaminergic systems and non-dopaminergic (e.g. cholinergic, noradrenergic, serotoninergic) systems. The type and severity of NMS vary based on age, disease severity, and predominant motor symptoms. NMS can be disabling and reduce quality of life. Treatment of NMS can be challenging. Some NMS are helped by dopaminergic treatment, whereas others can be induced or exacerbated by treatments that help the motor dysfunction. Physicians should probe their PD patients about their NMS and address them for better care. Clinical trials should incorporate NMS as outcomes for more meaningful conclusions on the effect of treatments under investigation.

show abstract

Visual dysfunction in Parkinson disease without dementia

Abstract: Patients with mild to moderate Parkinson disease showed impaired visual perception and cognition compared with elderly control subjects. Visual dysfunction contributes to parkinsonian disability through its influences on cognition and locomotion.

Cited by 274 publications

References 48 publications

Visual perception in prediagnostic and early stage Huntington's disease

Visual perception in prediagnostic and early stage Huntington's disease

Subjective visual vertical perception and sense of smell in Parkinson disease

Non-motor Symptoms in Parkinson’s Disease

Contact Info

Product

Resources

About